Exelixis registers Phase 3 STELLAR-316 trial of zanzalintinib in colorectal cancer MRD
Exelixis listed a new Phase 3 trial testing zanzalintinib with and without pembrolizumab combination against placebo in colorectal cancer patients with molecular residual disease.
Exelixis had one notable registry update during the week of August 6, 2026.
- Exelixis, with collaborator Merck Sharp & Dohme, registered "STELLAR-316" (NCT07750158), a randomized Phase 3 trial listed as recruiting. The study is designed to evaluate the effectiveness of zanzalintinib plus pembrolizumab combined with berahyaluronidase alfa, as well as zanzalintinib alone, compared with placebo1 in patients with Stage II or III colorectal cancer who have molecular residual disease after definitive therapy. The trial plans to enroll 600 participants1 and requires patients to be ctDNA-positive based on local testing using the Natera Signatera tissue-informed molecular residual disease assay1. Primary completion is estimated for April 5, 2030.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.